These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Gangliosides in acute myeloid leukaemia (AML) and non-Hodgkin's lymphoma (NHL).
    Author: Anh-Tuan N, Pick J, Mód A, Hollán SR.
    Journal: Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1003-7. PubMed ID: 3464433.
    Abstract:
    Gangliosides of human acute myelomonocytic leukaemia (AMMoL), acute monocytic leukaemia (AMoL) and lymphoblastoid (pre-B) lymphoma cells were analysed by overpressured thin-layer chromatography (OPTLC) followed by scanning densitometry. AMMoL cells were found to contain four gangliosides, viz. GM3 (47.2%), GM1 (31.8%), GD1a (7.5%) and an unidentified compound migrating between GM1 and GD1a (13.5%). In AMoL cells, six components were identified (GM3:51.3%, GM1:13.4%, GD3:7.8%, GD1a:4.7%, GD1b:6%, and an unidentified compound migrating between GM2 and GM1). The total gangliosides extracted from pre-B lymphoma cells of the hand-mirror variant were composed of 10 species (GM3:50.8%, GM2:11.2%, GM1:7.8%, GD3:2.3%, GD1a:1.1%, GD1b:2.2%, GT1:1.6%, and three unidentified components with chromatographic mobilities between GM2 and GD1a). Additional studies must still be performed to clarify the question as to whether ganglioside GD3 represent a qualitative glycolipid marker for AMoL and pre-B lymphoblastic lymphoma.
    [Abstract] [Full Text] [Related] [New Search]